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OBJECTIVES: To evaluate, in daily practice, the beneﬁts of
drotrecogin alfa (DA) in the treatment of severe septic patients
with multiple organ failure and optimum intensive care support.
METHODS: In this prospective, observational pre-post study,
the clinicians were free to include any patient meeting DA’s inclu-
sion criteria before and after DA’s marketing. An optimal
propensity score matching technique was used to reduce recruit-
ment bias. Survival was modeled using a Cox proportional
hazards model with a shared frailty term to account for the clus-
tering of patients within the intensive care units. The number of
bleeding events measured DA’s safety. RESULTS: Respectively
509 and 587 patients were included in the before and after
groups. There is strong evidence of recruitment bias: patients in
the after group are younger, more frequently ventilated, have less
comorbidities but more organ failures. After propensity score
matching, 840 patients were retained in the analysis, with a
better balance between the groups. The use of a frailty model
improves signiﬁcantly the variance explained by the survival
model, showing a non-negligible cluster effect. When consider-
ing the whole sample of patients, without adjustments, survival
is improved in the after (i.e. with DA) group (p = 2.5%), with a
hazard ratio (HR) of 0.805. In the matched sample, there are 
no signiﬁcant survival differences (HR = 0.900, p = 35.0%).
However, after stratifying by the LODS severity score quartiles,
signiﬁcance is reached (HR = 0.795, p = 4.8%). In the matched
sample, a negative binomial model best described bleeding
events. In this model, patients in the after group have a higher
mean of bleeding events (p = 2.0%). CONCLUSION: This
observational study conﬁrms DA’s clinical trial results in the real
practice setting. However, the use of the propensity score cannot
replace randomization to assure perfect balance for all patient
characteristics, measured and unmeasured. The results should
therefore be considered with caution.
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OBJECTIVES: To evaluate the cost effectiveness of entecavir in
reducing HBV DNA viral load(VL) and subsequent compensated
cirrhosis (CC), decompensate cirrhosis (DC), and hepatocellular
cancer(HCC). METHODS: The analytic perspective was that of
a third-party payer. We used patient-level drug exposure and VL
data from a randomized phase III trial of 715 HBeAg+ CHB
patients, and estimates of cost offsets and life expectancy gains
as a result of the prevention of projected clinical events. The mul-
tivariate-adjusted relative risks with VL categories were esti-
mated by Cox proportional hazards models from a Taiwan
cohort of 3851 CHB subjects with 42,115 person-years of
follow-up, and then applied to the trial patients whose VL were
measured at Week 48 to estimate event risks. Entecavir and
lamivudine were assigned daily prices of $19.43 and $6.14
respectively, based on recent First Data-Bank reports. Life
expectancy for DC and HCC was estimated by the declining
exponential approximation of life expectancy (DEALE) method.
Other model parameter values were derived from external
sources. The uncertainty surrounding event distribution and
treatment failure rates beyond trial period were considered using
probabilistic sensitivity analyses (PSA) with 1000 replicates.
RESULTS: Subjects were male (75%), Asian (57%) or white
(40%) with mean age 35 years. Entecavir was superior to
lamivudine for the proportion of subjects who achieved HBV
DNA < 300 copies/ml by PCR assay at Week 48 (67% versus
37% , respectively) (P < 0.05). One year of entecavir therapy
gained 0.7843 quality-adjusted life year (QALY) at an incre-
mental cost of $1607, with a 3% annual discount. Compared
with lamivudine, using entecavir cost an incremental $2049 per
QALY gained (95%CI: $688, $5134), with 98.8% of PSA-
derived estimates below $10,000/QALY. Results are robust and
most sensitive to treatment duration, efﬁcacy, and cost. CON-
CLUSIONS: Entecavir given for one year is clinically effective
and highly cost-effective in HBeAg+ patients.
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OBJECTIVE: To establish the clinical prognosis, costs and cost-
effectiveness of peginterferon alfa-2a (180mcg/week) plus rib-
avirin versus no treatment in patients with CHC and PNALT
from a Spanish national health care system (NHS) perspective.
METHODS: A Markov model was developed to simulate the
disease progression of 45-year old patients with CHC and
PNALT. Fibrosis progression rates in PNALT were obtained
from published studies. Efﬁcacy, in terms of sustained virologi-
cal response (SVR), for peginterferon alfa-2a plus ribavirin and
no treatment in patients with genotype 1 and genotype 2/3 was
obtained from a multinational, randomized, controlled trial. In
this trial, no patients in the control arm achieved an SVR. Tran-
sition probabilities and quality of life estimates were obtained
from published literature. Unit costs were obtained from a
Spanish database. The discount rate employed was 3.5%.
RESULTS: In genotype 1 patients, peginterferon alfa-2a plus rib-
avirin compared with no treatment increases patients life
expectancy by 0.63 years (0.70 quality-adjusted life years
(QALYs)), yielding an incremental cost-effectiveness ratio
(ICER) of 14,729 €/ life year gained (LYG) (€13,388/QALY). In
genotype 2/3 patients, peginterferon alfa-2a plus ribavirn
increases life expectancy by 1.14 years (1.26 QALYs), yielding
an ICER of 109 €/LYG (99 €/QALY). The overall ICER based
on the genotype distribution in the trial is €11,374/LYG
(€9952/QALY). CONCLUSIONS: From the Spanish NHS per-
spective, peginterferon alfa-2ª (40KD) (PEGASYS®) plus rib-
avirin (COPEGUS®) in patients with CHC and PNALT is a
cost-effective treatment option, regardless of HCV genotype.
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OBJECTIVE: To evaluate the cost-effectiveness of the empirical
use of moxiﬂoxacin in community-acquired pneumonia (CAP)
taking into account clinical failure caused by prevailing levels of
antimicrobial resistance in France, Germany and the US repre-
senting high, low and moderate levels of resistance respectively.
METHODS: Only anecdotal evidence is available in the litera-
ture on the direct link between resistance and clinical failure. A
